Recent Label Updates for Apotex's Ruxolitinib
Apotex's ruxolitinib (generic for Jakafi/Opzelura) received FDA-approved label changes in 2024 adding precautions for serious infections, including tuberculosis (TB), and emphasizing screening before starting treatment. The update warns of increased risk for bacterial, viral, fungal, and protozoal infections due to JAK inhibitor immunosuppression, with specific mention of TB reactivation. Providers must screen patients for latent TB and test for hepatitis B and C prior to initiation.[1][2]
Why the Infection Warnings Now?
These additions stem from post-marketing data and clinical trials showing higher infection rates in ruxolitinib users compared to placebo. Secondary prophylaxis for Pneumocystis jirovecii pneumonia and herpes zoster is now recommended for at-risk patients. The label stresses avoiding ruxolitinib in active infections and monitoring closely.[1]
Impact on Topical vs. Oral Formulations
For the topical cream (Opzelura generic), warnings mirror oral versions but highlight local application risks like folliculitis or herpes simplex. Oral ruxolitinib carries broader systemic warnings, including progressive multifocal leukoencephalopathy (PML) reports.[2]
What Happens if Infections Develop?
Discontinue ruxolitinib if serious infections occur and evaluate promptly. The label advises against concurrent use with other immunosuppressants like biologics or strong CYP3A4 inhibitors, which raise exposure levels.[1][2]
Comparison to Branded Jakafi Warnings
Apotex's labeling aligns with Incyte's Jakafi updates from the same period, driven by shared JAK inhibitor class effects. No Apotex-specific deviations noted; generics typically adopt innovator safety data.[1]
[1]: FDA Label for Apotex Ruxolitinib Cream
[2]: FDA Label for Apotex Ruxolitinib Tablets